NCT00171860View on ClinicalTrials.gov

A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

July 31, 2007

Conditions
Hypereosinophilic Syndrome
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

Unknown

Novartis Investigative Site, Leuven

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY